Home/Pipeline/ARX305

ARX305

Oncology (unspecified)

Phase 1Active

Key Facts

Indication

Oncology (unspecified)

Phase

Phase 1

Status

Active

Company

NovoCodex Biopharmaceuticals

About NovoCodex Biopharmaceuticals

A Chinese biotech developing precision ADCs using synthetic amino acid site-specific conjugation technology for cancer treatment.

View full company profile

Therapeutic Areas

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active
DDX3 Inhibitor (Oncology)	Lead Discovery Siena	Discovery	Active